PMID- 28189400
OWN - NLM
STAT- MEDLINE
DCOM- 20171213
LR  - 20231112
IS  - 1873-2518 (Electronic)
IS  - 0264-410X (Print)
IS  - 0264-410X (Linking)
VI  - 35
IP  - 10
DP  - 2017 Mar 7
TI  - Heritability of vaccine-induced measles neutralizing antibody titers.
PG  - 1390-1394
LID - S0264-410X(17)30158-5 [pii]
LID - 10.1016/j.vaccine.2017.01.078 [doi]
AB  - Understanding how genetics influences inter-individual variation of antibody 
      titers in response to measles vaccination is vital to understanding possible 
      sources of vaccine failure as well as improved vaccine development. Although it 
      is recognized that both the human leukocyte antigen (HLA) genes and the 
      immunoglobulin allotype genes play significant roles in immune response, there is 
      significant variation in antibody titers that is not explained by these genes. To 
      obtain a more complete estimate of the role of the entire genome, we used a large 
      panel of single nucleotide polymorphisms to estimate the heritability of antibody 
      response to measles vaccine. Based on 935 subjects with European ancestry, we 
      estimated the heritability to be 49% (standard error 0.17). We also estimated the 
      heritability attributable to each chromosome, and found a large range in 
      chromosome-specific heritabilities. Notably, chromosome 1 had the largest 
      estimate (28%), while chromosome 6, which harbors HLA, had an estimated 
      heritability of 13%. Compared with a prior study of twins in the same community, 
      which resulted in a heritability estimate of 88.5%, our study suggests there are 
      either many rare genetic variants, or many common genetic variants of small 
      effect sizes that contribute to variations of antibody titers in response to 
      measles vaccine.
CI  - Copyright (c) 2017 Elsevier Ltd. All rights reserved.
FAU - Schaid, Daniel J
AU  - Schaid DJ
AD  - Division of Biomedical Statistics and Informatics, Department of Health Science 
      Research, Mayo Clinic, Rochester, MN 55905, USA.
FAU - Haralambieva, Iana H
AU  - Haralambieva IH
AD  - Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN 55905, USA.
FAU - Larrabee, Beth R
AU  - Larrabee BR
AD  - Division of Biomedical Statistics and Informatics, Department of Health Science 
      Research, Mayo Clinic, Rochester, MN 55905, USA.
FAU - Ovsyannikova, Inna G
AU  - Ovsyannikova IG
AD  - Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN 55905, USA.
FAU - Kennedy, Richard B
AU  - Kennedy RB
AD  - Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN 55905, USA.
FAU - Poland, Gregory A
AU  - Poland GA
AD  - Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN 55905, USA. 
      Electronic address: poland.gregory@mayo.edu.
LA  - eng
GR  - R01 AI033144/AI/NIAID NIH HHS/United States
GR  - R01 AI048793/AI/NIAID NIH HHS/United States
GR  - R01 AI121054/AI/NIAID NIH HHS/United States
GR  - R37 AI048793/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20170208
PL  - Netherlands
TA  - Vaccine
JT  - Vaccine
JID - 8406899
RN  - 0 (Antibodies, Neutralizing)
RN  - 0 (Antibodies, Viral)
RN  - 0 (Measles Vaccine)
SB  - IM
MH  - Adolescent
MH  - Antibodies, Neutralizing/*blood
MH  - Antibodies, Viral/*blood
MH  - Child
MH  - Cohort Studies
MH  - Female
MH  - Humans
MH  - Immunity, Humoral/*genetics
MH  - Male
MH  - Measles/*immunology/*prevention & control
MH  - Measles Vaccine/administration & dosage/*immunology
MH  - Young Adult
PMC - PMC5548390
MID - NIHMS891758
OTO - NOTNLM
OT  - Adult
OT  - Cellular
OT  - Genetic variation
OT  - Genome-wide association study
OT  - Heritability
OT  - Humoral
OT  - Immunity
OT  - Measles
OT  - Measles vaccine
OT  - Polymorphism
OT  - Single nucleotide
COIS- Competing Interests: Dr. Poland is the chair of a Safety Evaluation Committee for 
      novel investigational vaccine trials being conducted by Merck Research 
      Laboratories. Dr. Poland offers consultative advice on vaccine development to 
      Merck & Co. Inc., CSL Biotherapies, Avianax, Dynavax, Novartis Vaccines and 
      Therapeutics, Emergent Biosolutions, Adjuvance, Microdermis, Seqirus, NewLink, 
      Protein Sciences, GSK Vaccines, and Sanofi Pasteur. Drs. Poland and Ovsyannikova 
      hold three patents related to measles and vaccinia peptide research. Dr. Kennedy 
      has received funding from Merck Research Laboratories to study waning immunity to 
      measles and mumps after immunization with MMR-II(R). These activities have been 
      reviewed by the Mayo Clinic Conflict of Interest Review Board and are conducted 
      in compliance with Mayo Clinic Conflict of Interest policies. This research has 
      been reviewed by the Mayo Clinic Conflict of Interest Review Board and was 
      conducted in compliance with Mayo Clinic Conflict of Interest policies.
EDAT- 2017/02/13 06:00
MHDA- 2017/12/14 06:00
PMCR- 2018/03/07
CRDT- 2017/02/13 06:00
PHST- 2016/11/21 00:00 [received]
PHST- 2017/01/16 00:00 [revised]
PHST- 2017/01/30 00:00 [accepted]
PHST- 2017/02/13 06:00 [pubmed]
PHST- 2017/12/14 06:00 [medline]
PHST- 2017/02/13 06:00 [entrez]
PHST- 2018/03/07 00:00 [pmc-release]
AID - S0264-410X(17)30158-5 [pii]
AID - 10.1016/j.vaccine.2017.01.078 [doi]
PST - ppublish
SO  - Vaccine. 2017 Mar 7;35(10):1390-1394. doi: 10.1016/j.vaccine.2017.01.078. Epub 
      2017 Feb 8.